The first result for the reimbursement for the remaining 13 indications of Keytruda was ultimately a collective ‘hold.’ However, the reimbursement journey for 'Keytruda' has just begun.

The Health Insurance Review and Assessment Service held its first Cancer Disease Deliberation Committee meeting of the new year on January 31st and reviewed the reimbursement of the remaining 6 indications for MSD Korea's PD-1 inhibitor immuno-oncology drug Keytruda (pembrolizumab) that were not reviewed last year, and issued another re-deliberation decision.

This completes the first round of reviews for Keytruda’s 13 indications for which the company applied for reimbursement in June last year. 3 indi